Aduragbemi Omiyale
By Aduragbemi Omiyale
The Nigerian Exchange (NGX) Limited will soon welcome a new member to its trading platform and this is Mecure Industries Limited, a leading human pharmaceuticals and nutraceuticals manufacturing company.
A statement on Monday from the local bourse disclosed that the healthcare firm would list 4 billion ordinary shares by introduction at N2.96 per share, boosting its market capitalisation by N11.84 billion.
It was stated that Mecure Industries would be on the NGX Main Board, though the date for the listing was not disclosed in the statement.
For more than a decade, Mecure Industries Plc has tapped into the power of new technology and innovation to advance the practice of medicine.
The organisation pioneered the development of novel products based on advances in technology and launched the pharmaceutical industry’s first tablet in a capsule formulation called Liquitab Floatcap.
Today, as a leading healthcare company serving millions of patients, Mecure continues to be an entrepreneurial, technology‐driven enterprise dedicated to helping people fight everyday illness.
With Mecure listing on the exchange, NGX further reinforces itself as a platform of choice for corporates looking to raise capital.
Already, the bourse has secured listings from VFD Group, Nigeria Infrastructure Debt Fund (NIDF) and Africa Plus Partners in 2023.
NGX continues to strengthen its value proposition for corporates to consider the Nigerian capital market for their fundraising needs, reinventing itself and maintaining advocacy with policymakers and regulators to make listing in the public markets attractive.
